一名肾功能不全患者单次注射地诺单抗后发生严重低钙血症。
Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment.
作者信息
Talreja Draupadi B
机构信息
Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CAUSA.
出版信息
J Drug Assess. 2012 Feb 21;1(1):30-3. doi: 10.3109/21556660.2012.668504. eCollection 2012.
Abstract
Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe hypocalcemia after receiving denosumab.
摘要
对于使用地诺单抗（每6个月60毫克）的患者，无需监测肾功能或针对肾功能受损患者调整剂量。然而，这些患者发生低钙血症的风险增加。本病例报告描述了一名肾功能受损患者在接受地诺单抗治疗后发生严重低钙血症的情况。
相似文献
1
Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment.
J Drug Assess. 2012 Feb 21;1(1):30-3. doi: 10.3109/21556660.2012.668504. eCollection 2012.
2
Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Support Care Cancer. 2015 Jun;23(6):1657-62. doi: 10.1007/s00520-014-2521-8. Epub 2014 Nov 25.
3
Severe hypocalcemia following denosumab injection in a hemodialysis patient.
Am J Kidney Dis. 2012 Oct;60(4):626-8. doi: 10.1053/j.ajkd.2012.06.019. Epub 2012 Jul 31.
4
Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Am J Nephrol. 2015;41(2):129-37. doi: 10.1159/000380960. Epub 2015 Mar 18.
5
[Hypocalcemia Induced by Denosumab in Patients with Renal Insufficiency].
Gan To Kagaku Ryoho. 2016 Jul;43(7):875-8.
6
Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Intern Med. 2015;54(20):2637-42. doi: 10.2169/internalmedicine.54.4946. Epub 2015 Oct 15.
7
Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
J Nephrol. 2017 Apr;30(2):271-279. doi: 10.1007/s40620-016-0334-1. Epub 2016 Jul 9.
8
Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature.
Case Rep Nephrol. 2019 Mar 21;2019:3027419. doi: 10.1155/2019/3027419. eCollection 2019.
9
Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
Therapie. 2017 Jun;72(3):383-385. doi: 10.1016/j.therap.2016.07.003. Epub 2016 Sep 15.
10
Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review.
Case Rep Oncol Med. 2018 Oct 14;2018:2059364. doi: 10.1155/2018/2059364. eCollection 2018.
引用本文的文献
1
Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study.
Bone Rep. 2022 Nov 7;17:101635. doi: 10.1016/j.bonr.2022.101635. eCollection 2022 Dec.
2
Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Osteoporos Int. 2020 Apr;31(4):655-665. doi: 10.1007/s00198-019-05261-7. Epub 2019 Dec 14.
3
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
Ther Adv Musculoskelet Dis. 2018 Oct 22;10(11):209-223. doi: 10.1177/1759720X18805759. eCollection 2018 Nov.
4
High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Clin Interv Aging. 2018 Oct 8;13:1929-1934. doi: 10.2147/CIA.S180614. eCollection 2018.
5
Calcium use in the management of osteoporosis: continuing questions and controversies.
Curr Osteoporos Rep. 2014 Dec;12(4):396-402. doi: 10.1007/s11914-014-0234-z.
6
Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases.
Osteoporos Int. 2014 Feb;25(2):777-82. doi: 10.1007/s00198-013-2585-1. Epub 2013 Dec 6.
本文引用的文献
1
Effects of denosumab on fracture and bone mineral density by level of kidney function.
J Bone Miner Res. 2011 Aug;26(8):1829-35. doi: 10.1002/jbmr.403.
2
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
3
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.
4
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.
5
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
6
Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
J Postgrad Med. 2008 Jul-Sep;54(3):237. doi: 10.4103/0022-3859.41815.
7
Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
J Palliat Med. 2007 Dec;10(6):1226-7. doi: 10.1089/jpm.2007.0113.
8
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Clin Genitourin Cancer. 2007 Sep;5(6):403-5. doi: 10.3816/CGC.2007.n.025.
9
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312.
10
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
Zotero 插件